Otezla maker Amgen challenges patient groups to help fix long-lasting psoriasis treatment gaps

What to do when new, better treatments for a condition are available but fewer people are seeking them out?

If you're Amgen, looking to fill gaps in psoriatic disease treatment, you launch a brainstorming contest.

The California drugmaker, which markets the psoriasis pill Otezla and longtime standard therapy Enbrel, is calling on patient groups of all sizes and localities to take their shot at answering a seemingly mundane question: How can psoriatic disease patients work with their doctors to get better results from treatment?